NHS set to benefit from £23 million following CMA pharma probe

News Competition Sanctions & Fines

Date: 10th Dec, 2024 Source: Competition and Markets Authority Country: United Kingdom Original Source

Brief

"On January 10, 2024, the Competition and Markets Authority issued an update regarding NHS set to benefit from £23 million following CMA pharma probe. The investigation focused on intravenous iron treatments, and Vifor Pharma agreed to address competition concerns by making a payment of £23 million and introducing measures to prevent misinformation about rival treatment Monofer."

This content is restricted.

Highlights content goes here...

This content is restricted.

Competition and Markets Authority

RADA.AI

Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?

Suggested

NHS set to benefit from £23 million following CMA pharma probe

Brief

Competition and Markets Authority

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.

NHS set to benefit from £23 million following CMA pharma probe

Brief

Competition and Markets Authority

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify OTP

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.